The ICIs used to treat SCLC include inhibitors of programmed cell death 1 (PD-1), programmed cell death ligand (PD-L1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) (6). Here, CTLA4 is linked to small cell lung carcinoma.